Corpus Intelligence IC Memo — HIGHLANDS HOSPITAL 2026-04-26 14:08 UTC
IC Memo — HIGHLANDS HOSPITAL
Investment Committee Memorandum | PA | 61 beds | Grade D | EBITDA uplift $1.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HIGHLANDS HOSPITAL

CCN 390184 | FAYETTE, PA | 61 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

HIGHLANDS HOSPITAL is a 61-bed community hospital in FAYETTE, PA with $22.0M in net patient revenue and a -56.5% operating margin. The hospital serves a payer mix of 0.0% Medicare, 1.5% Medicaid, and 98.5% commercial.

Thesis: Turnaround. Our ML models identify $1.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -56.5% to -49.1% (+736bps).

Net Revenue HCRIS$22.0M
Current EBITDA COMPUTED$-12.4M
Operating Margin COMPUTED-56.5%
Occupancy HCRIS34.0%
Revenue / Bed COMPUTED$360K
Net-to-Gross HCRIS32.3%
Distress Probability MLnan%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
87
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -56.5% places it below the state median. Among 87 size-comparable peers (30-122 beds), the median margin is 1.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (30-122), prioritizing same-state peers. 87 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HIGHLANDS HOSPITAL (Target)PA61$22.0M-56.5%
THE GETTYSBURG HOSPITALPA76$341.8M18.4%
EPHRATA COMMUNITY HOSPITALPA115$291.8M3.8%
AMERICAN ONCOLOGIC HOSPIALPA100$229.8M-11.1%
EVANGELICAL COMMUNITY HOSPITALPA119$223.6M5.1%
ST. LUKES HOSPITAL - MONROE CAPA98$221.8M7.8%
GEISINGER LEWISTOWN HOSPITALPA107$210.8M11.2%
UPMC HANOVERPA73$200.8M18.2%
MEMORIAL HOSPITALPA80$184.5M13.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$462K+210bp18mo
Cost to Collect4.5%2.5%$440K+200bp12mo
Denial Rate Reduction12.0%6.5%$435K+198bp12mo
A/R Days Reduction5200.0%3800.0%$267K+122bp9mo
Clean Claim Rate88.0%96.0%$14K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$462K
Cost to Collect
$440K
Denial Rate Reduction
$435K
A/R Days Reduction
$267K
Clean Claim Rate
$14K
Total EBITDA Uplift$1.6M
Current EBITDA$-12.4M
+ RCM Uplift+$1.6M
Pro Forma EBITDA$-10.8M
Current Margin-56.5%
Pro Forma Margin-49.1%
WC Released (1x)$843K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-19.1M$-65.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-19.1M$-78.5M0.00x-100.0%
Bull Case9.0x11.0x$-17.2M$-79.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-17.2M$-91.6M0.00x-100.0%
Bear Case11.0x10.0x$-21.0M$-67.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-21.0M$-81.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 34.0%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 87 hospitals with 30-122 beds
  • Same-state prioritization (n=88)
  • Comp margins: P25=-18.0% / P50=1.2% / P75=9.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.